News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase I
Blueprint Medicines (BPMC) Announces Proof-Of-Concept Data From Phase 1 Clinical Trial Of BLU-285 In Patients With Advanced Systemic Mastocytosis 12/5/2016
AbbVie (ABBV) Release: IMBRUVICA (ibrutinib) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5-Year Analysis And Long-Term RESONATE-2 Follow-Up Data At American Society of Hematology 2016 Show Lasting Efficacy 12/5/2016
Akari Therapeutics Announces Corporate Update With New Positive Clinical Data And A New Pipeline Of Tick Derived And Engineered Proteins 12/5/2016
Zynerba (ZYNE) Reports Positive Results For ZYN002 CBD Gel In Phase I Studies At 70th Annual Meeting Of The American Epilepsy Society 12/5/2016
EyeGate Pharma Reports Positive Data From Third Stage Of Phase Ib/IIa Clinical Trial Of EGP-437 In Cataract Surgery Patients 12/5/2016
Celldex (CLDX) Presents Data On CDX-1140, A Novel CD40 Agonist Antibody For Hematologic And Solid Malignancies, At The American Society of Hematology Annual Meeting 12/5/2016
MabVax Therapeutics Expands Phase I Clinical Trial Investigation For Patients With Pancreatic Cancer To Include Honorhealth Research Institute 12/5/2016
Children's Hospital of Philadelphia Release: After One Dose Of Gene Therapy, Hemophilia B Patients Maintain Near-Normal Levels Of Clotting Factor 12/5/2016
Matinas BioPharma Commences Dosing In Phase I Study Of Orally Administered Aminoglycoside Antibiotic MAT2501 12/5/2016
Sunesis (SNSS) Announces Presentation Of Results From Completed Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK Inhibitor SNS-062 At American Society of Hematology Annual Meeting 12/5/2016
Global Blood Therapeutics (GBT) Announces New Long-Term Clinical Data From Ongoing Phase I/II Trial Of GBT440 In Sickle Cell Disease At American Society of Hematology 12/5/2016
AbbVie (ABBV) Release: Favorable Response Rates Suggest Promise Of Ibrutinib (IMBRUVICA) Combination Therapy In Two Common Types Of Non-Hodgkin's Lymphoma 12/5/2016
Juno (JUNO) Shows Off Positive Early Data in Leukemia Patients 12/5/2016
Struggling Alnylam (ALNY) Attempts to Reboot Itself With Promising Hemophilia Data 12/5/2016
Daiichi Sankyo Presents Phase 1 Data For MDM2 Inhibitor DS-3032 In Acute Myeloid Leukemia And Myelodysplastic Syndrome At The 58th Annual Meeting Of The American Society of Hematology 12/5/2016
Children's Hospital of Philadelphia Release: In Clinical Trials, CAR T Cell Immunotherapy Continues To Yield Complete Responses In Children & Young Adults With Relapsed And Refractory Leukemia 12/5/2016
American Society of Hematology Release: Bioengineering Innovations Show Promise For Improving Treatments And Drug Delivery 12/5/2016
Top 7 Jaw-Dropping Pipeline Blowups This Year 12/5/2016
As Rival Juno (JUNO) Falters, Kite Pharma (KITE) Touts New CAR-T Data and Maps Out BLA Submission Plans 12/5/2016
Juno (JUNO) Presents Data From TRANSCEND Study Showing 60% Complete Response In Patients With Relapsed Or Refractory Aggressive CD19+ Non-Hodgkin Lymphoma 12/5/2016
Seattle Genetics (SGEN) Highlights Long-Term Follow-Up Data From ADCETRIS® (Brentuximab Vedotin) In T-Cell Lymphomas At American Society of Hematology Annual Meeting 12/5/2016
Alnylam (ALNY) Presents Updated Results From Phase I/II Study Of ALN-CC5 In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) 12/5/2016
AstraZeneca PLC (AZN) Release: Early Data Demonstrate Clinical Activity Of Acalabrutinib In Difficult-To-Treat Chronic Lymphocytic Leukemia 12/5/2016
Seattle Genetics (SGEN) Highlights Phase I Vadastuximab Talirine (SGN-CD33A; 33A) Data Presentations, Including Combination Therapy With HMAs, In Patients With Acute Myeloid Leukemia At American Society of Hematology Annual Meeting 12/5/2016
AmpliPhi Bio (APHB) Reports Favorable Final Results From Phase I Trial Of AB-SA01 12/5/2016
Merck & Co. (MRK) Release: Updated KEYTRUDA (Pembrolizumab) Findings In Patients With Relapsed Or Refractory Primary Mediastinal Large B-Cell Lymphoma Presented At 58th Annual Meeting Of The American Society of Hematology 12/5/2016
Mersana Presents Updated Data On Investigational Cancer Antibody Drug Conjugate At World Conference On Lung Cancer 12/5/2016
Bristol-Myers Squibb (BMY) Release: Encouraging Survival Observed With Opdivo (Nivolumab) Plus Yervoy(Ipilimumab) With Longer Follow-Up In First-Line Advanced Non-Small Cell Lung Cancer, In Updated Phase 1b Checkmate -012 Study 12/5/2016
Celltrion Healthcare (068270.KQ) Presents Positive Results For CT-P10, Biosimilar Rituximab Candidate, In Newly Diagnosed Advanced Stage Follicular Lymphoma 12/5/2016
Acetylon Presents Early Phase 1a/1b Results For Citarinostat (ACY-241) In Combination With Pomalyst And Dexamethasone Showing Promising Treatment Responses In Relapsed Or Relapsed-And-Refractory Multiple Myeloma 12/5/2016
Autolus Release: New CAR-T Approach For The Treatment Of T-Cell Lymphomas Presented At The 2016 American Society of Hematology Annual Meeting 12/5/2016
BerGenBio AS Presents Promising Phase I Clinical & Biomarker Data From First In Class Axl Inhibitor BGB324 In AML At American Society of Hematology 2016 12/2/2016
bluebird bio (BLUE), Celgene (CELG)'s Multiple Myeloma CAR-T Drug Shines in Tiny Study 12/2/2016
Apellis Pharma Reports Positive Interim Results From Phase Ib Clinical Trials Of APL-2 In PNH 12/2/2016
NeuroDerm (NDRM) Announces Top-Line Results Of Pilot PK Trial Comparing ND0701 With Commercial Apomorphine 12/2/2016
Acetylon Announces Upcoming Scientific Presentations On The Use Of Selective HDAC Inhibitors In Treating Genetic Blood Disorders And Cancers 12/2/2016
Ensysce Biosciences Inc. Initiates Phase 1 Clinical Trial To Study PF614, BIO-MD Prodrug Of Oxycodone 12/2/2016
Helix Biopharma (TSX:HBP) Accelerates Escalation Of L-DOS47 Dosing In The U.S. Phase I Study 12/2/2016
Cyclacel Pharma (CYCC)’s Novel PLK1 Inhibitor, CYC140, Demonstrates Therapeutic Potential In Esophageal Cancer And Acute Leukemia 12/1/2016
Cellectar Biosciences  (CLRB) Announces Results From The First Two Cohorts Of Its CLR 131 Phase I Trial: Demonstrates Excellent Efficacy, Overall Survival Benefit, And Progression Free Survival Similar To Or Better Than Recently Approved Therapies 12/1/2016
Global Blood Therapeutics (GBT) Announces Upcoming Investor Webcast To Review GBT440 Data Being Presented At American Society of Hematology That Support Sickle Cell Disease Program 12/1/2016
Arsanis Receives FDA Fast Track Designation For ASN100 For The Prevention Of Staphylococcus Aureus Pneumonia 12/1/2016
Deciphera Reports Encouraging Clinical Results With DCC-2618 In Genetically-Defined Cancers With Drug Resistant Mutations 12/1/2016
ERYtech Pharma Presents New Data On GRASPA’s Mechanism Of Action At American Society of Hematology Annual Meeting 12/1/2016
Cellular Biomedicine Group (CBMG), A China-US Biopharma, Starts China Trial Of CAR-T Immunotherapy 12/1/2016
Ignyta (RXDX) Announces Compelling Phase I/Ib Clinical Data On RXDX-105, Its VEGFR-Sparing RET Inhibitor, At The 2016 EORTC-Ignyta (RXDX)-NCI Annual Meeting 12/1/2016
Blueprint Medicines (BPMC) Announces Proof-Of-Concept Data From Phase 1 Clinical Trial Of BLU-285 In Patients With Advanced Gastrointestinal Stromal Tumors 12/1/2016
Sorrento (SRNE)'s TNK Therapeutics Provides Progress Update For Its Anti-CD38 And CD123 CAR-T Programs For Treatment Of Hematological Malignancies 12/1/2016
MicuRx Pharma Initiates Phase 1 Clinical Trial In U.S. For Novel Antibiotic Agent MRX-4 11/30/2016
Agenus (AGEN) Announces Commencement Of Phase 1/2 Clinical Trial Of Anti-OX40 Checkpoint Antibody INCAGN1949 In Patients With Solid Tumors 11/30/2016
Oramed (ORMP)'s ORMD-0901 (Oral GLP-1 Analog) Found Safe And Well Tolerated In Phase Ib Study 11/29/2016
Blueprint Medicines (BPMC) Announces Proof-Of-Concept Data From Global Phase 1 Clinical Trial Of BLU-554 In Patients With Advanced Hepatocellular Carcinoma 11/29/2016
OncoMed (OMED) Presents Initial First-In-Human Data For Anti-DLL4/VEGF Bispecific And Anti-RSPO3 At The 28th EORTC-NCI-AACR Molecular Targets And Cancer Therapeutics Symposium 11/29/2016
Galapagos (GLPG.BR) Initiates Phase 1 Study With Cystic Fibrosis Drug GLPG2737 11/29/2016
OncoPep Announces Initiation Of Phase 1b Clinical Trial Of PVX-410 In Smoldering Multiple Myeloma And Upcoming Presentation Of Positive Results From Phase 1/2a Clinical Trial At American Society of Hematology 11/28/2016
Cidara (CDTX)’s Presentations At American Society of Hematology 2016 To Highlight Potential Role Of Novel Antifungal CD101 In Patients With Hematologic Malignancies 11/28/2016
MabVax Therapeutics Enrolls First Patients In Expansion Of Phase I Clinical Trial Treating Newly Diagnosed Pancreatic Cancer Patients 11/28/2016
PharmaMar Begins A Phase I Study Of PM1183 In Japan For The Treatment Of Solid Tumors 11/28/2016
Nature Cell Receives U.S. FDA Approval For Phase I And II Alzheimer's Clinical Trial 11/28/2016
The Franchise That Could Bring in Another $20 Billion for Celgene (CELG) 11/23/2016
5 Drug Giants That Could Dominate the $13 Billion Alzheimer's Market 11/23/2016
European Commission (EC) Approves Bristol-Myers Squibb (BMY)'s Opdivo(Nivolumab) For The Treatment Of Adult Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant And Treatment With Brentuximab Vedotin 11/23/2016
NantKwest Announces Landmark Study Published On high affinity haNK Cell Therapy In The Journal Oncotarget 11/23/2016
Viral Gene Announces Breakthrough In Colon Cancer: New Vaccine Targets Enzyme To Help Destroy Metastatic Tumor Cells 11/22/2016
YiSheng BioPharma Announces Completion Of Phase I Clinical Study Of A Novel Hepatitis B Vaccine With PIKA Adjuvant 11/21/2016
Apellis Pharma To Present Safety And Efficacy Data From Clinical Trials Of APL-2 In PNH At December Scientific Meetings 11/21/2016
Cortice Biosciences Announces Presentation Of Results From A Phase I/II Clinical Trial Evaluating TPI 287 For Treatment Of Recurrent Glioblastoma At The 21st Annual Scientific Meeting Of The Society Of Neuro-Oncology 11/21/2016
Agios (AGIO) Announces Phase I Data From Dose Expansion Cohorts Of AG-120 In Patients With IDH1 Mutant Positive Glioma And Chondrosarcoma 11/21/2016
MaaT Pharma Announces First Positive DSMB Safety Review And Continuation Of Its Phase 1b ODYSSEE Study 11/18/2016
Mallinckrodt (MNK) Release: Clinical Pharmacokinetic And Health Economic Data On OFIRMEV (Acetaminophen) Injection Presented At 15th Annual Pain Medicine Meeting Of ASRA 11/18/2016
Hutchison China MediTech (Chi-Med) Reports Positive Data From Phase I Trial Of Syk Inhibitor 11/18/2016
Cellectar Biosciences  (CLRB) Announces Successful Conjugation Of Multiple Pierre Fabre Cytotoxic Compounds To PDC Delivery Platform; Initiates In Vivo Studies For Solid Tumors 11/17/2016
Resverlogix (RVX.TO) Announces Successful Phase 1 Renal Trial Results: Clears Path For Future Phase 2 Studies 11/17/2016
Neon Therapeutics Announces First Patient Enrolled In Inaugural Clinical Trial For Personalized Cancer Vaccine NEO-PV-01 11/17/2016
OSE Immunotherapeutics Announces The Online Publication Of Positive Phase I Clinical Results With FR104 In The Journal Of Immunology 11/17/2016
Ra Pharma (RARX) Receives Orphan Drug Designation In The European Union For RA101495 For Treatment Of Paroxysmal Nocturnal Hemoglobinuria 11/17/2016
DBV Tech, BioNet-Asia And Geneva University Hospitals Complete Dosing In First Cohort Of Phase I Study Of Viaskin Rpt For Booster Vaccination Against Pertussis 11/17/2016
China Takes Lead in CRISPR Race, Will Test on a Human for the First Time 11/16/2016
Boehringer Ingelheim Bevacizumab Biosimilar Candidate Demonstrates Bioequivalence To Avastin 11/16/2016
FDA Grants Orphan Drug Designation To Amplyx For APX001 For Treatment Of Multiple Invasive Fungal And Mold Infections 11/16/2016
Imara Announces First Subject Dosed In Phase 1 Study Of Lead Product Candidate, IMR-687 11/16/2016
Cellectis (ALCLS) Announces Successful cGMP Manufacturing For Second Product Candidate: UCART123 11/16/2016
Viking Therapeutics (VKTX) Presents New Clinical Data On VK2809 In Subjects With Elevated Cholesterol At AHA Scientific Sessions 2016 11/15/2016
Ionis Pharma (IONS) Reports Positive Clinical Data From IONIS-ANGPTL3-L Rx 11/15/2016
Samumed Presents Data For A Small Molecule Modulator Of Wnt Pathway As A Potential Treatment For Degenerative Disc Disease 11/15/2016
3 Reasons That Make Biogen (BIIB) the King of a Crumbling Empire 11/14/2016
Boston Biomedical Announces Orphan Drug Designation For Napabucasin In Pancreatic Cancer 11/14/2016
CytRx (CYTR) Presents Positive Interim Results From On-Going Phase 1b/2 Aldoxorubicin Combination Clinical Trial At The 2016 CTOS Annual Meeting 11/14/2016
Cognition Therapeutics Announces Dosing Of First Alzheimer's Patient In Phase 1b Trial Of CT1812 11/14/2016
MabVax Therapeutics Reports Interim Safety And Imaging Results From Phase I Clinical Trials In Humab-5B1 Antibody Development Programs 11/14/2016
Oncobiologics (ONSIU) Announces Presentation Of Final Data From Phase I Clinical Study Of ONS-3010 (HUMIRA Biosimilar) 11/14/2016
Inovio Pharma (INO)’s Cancer Immunotherapy (INO-3112) Generates T Cell Immune Responses In Tumor Tissue And Peripheral Blood In Patients With HPV-Associated Head And Neck Cancer 11/14/2016
Idera Pharma (IDRA) Reports Translational Data Supporting The Mechanism Of Action Of Intratumoral IMO-2125 From Ongoing Phase I Dose Escalation In Clinical Trial In Combination With Ipilimumab In Metastatic Melanoma Patients Refractory To Anti-PD-1 Treatment 11/14/2016
Stealth Biotherapeutics Initiates Phase 1 Study Of Elamipretide In Dry Age-Related Macular Degeneration 11/14/2016
ARMO BioSciences' Immunotherapy AM0010 Receives Orphan Drug And Fast Track Designations From The U.S. FDA For The Treatment Of Pancreatic Cancer 11/14/2016
Arrowhead Pharma (ARWR) Presents New Data On ARC-AAT 11/14/2016
Hutchison China MediTech (Chi-Med) Presents Phase I Clinical Data For Selective Syk Inhibitor HMPL-523 At The 2016 American College of Rheumatology/ARHP Annual Meeting 11/14/2016
MiNA Presents Data Demonstrating Survival Benefit Of MTL-CEBPA In Animal Model Of Liver Failure At AASLD Liver Meeting 11/14/2016
LEAP Technologies Presents Data From Phase 1 Study Of GITR Agonist 11/14/2016
Alnylam (ALNY) And The Medicines Company (MDCO) Announce Publication Of Phase 1 Clinical Data With Inclisiran (ALN- PCSsc) In The New England Journal of Medicine 11/14/2016
Celltrion Healthcare (068270.KQ) Showcases Data Supporting Efficacy And Safety Of Both CT-P10 And CT-P13 Biosimilars 11/14/2016
Advaxis (ADXS) To Present Phase I Combination Data And New Preclinical Data Using AXAL At Upcoming Society For Immunotherapy Of Cancer (SITC) 2016 Annual Meeting 11/11/2016
Corvus Pharma Announces Preliminary Phase 1/1b Clinical Data With Lead Checkpoint Inhibitor CPI-444 Demonstrating Safety And Evidence Of Anti-Tumor Activity As A Single Agent In Patients With Advanced Refractory Cancers 11/11/2016
TRACON Pharma (TCON) Announces Presentation Of Updated Data From Phase Ib/II Study Of TRC105 And Votrient In Patients With Angiosarcoma 11/11/2016
Enanta Pharmaceuticals, Inc. Announces New Data On FXR Agonist EDP-305 For Non-Alcoholic Steatohepatitis (NASH) At The Liver Meeting 2016 11/11/2016
ImmunoGen (IMGN) To Present Preclinical Data Highlighting Potential Of Combining Mirvetuximab Soravtansine With An Immune Checkpoint Inhibitor At SITC 2016 Annual Meeting 11/11/2016
Botanix Accelerates Clinical Program With First Human Study 11/11/2016
Curis (CRIS) Presents Early Clinical Pharmacokinetic And Biomarker Data From CA-170’s Phase I Trial At The SITC 2016 Conference 11/10/2016
Infinity Pharma (INFI) Announces Second Publication On PI3K-Gamma In Nature 11/10/2016
Nektar Therapeutics (NKTR) Presents New Clinical Data From Ongoing Phase 1 Dose-Escalation Study Of NKTR-214 At The Society For Immunotherapy Of Cancer (SITC) 2016 Annual Meeting 11/10/2016
Assembly Biosciences Initiates Phase I Clinical Program Of ABI-H0731 For Treatment Of Chronic Hepatitis B Virus Infection 11/9/2016
Innate Pharma (IPH.PA ) Stock Falls Then Bounces Back as Prelim Opdivo Combo Data Fails to Impress 11/9/2016
Asterias Biotherapeutics Announces Treatment Of First Spinal Cord Injury Patient With Maximum Dose Of AST-OPC1 In SCiStar Clinical Trial 11/9/2016
Eloxx Pharma Announces Orphan Drug Designation In The U.S. And Europe For ELX-02 In Mucopolysacchardisis Type 1 (MPS 1) 11/8/2016
Zosano (ZSAN) Announces Completion Of Enrollment In Pivotal Efficacy Trial For M207 For Acute Migraine 11/8/2016
Elanix Technologies Strategic Partner, Transwell Biotechnology, Receives U.S. FDA Clearance For Phase I/II Clinical Trial Using Fibroblast Progenitors TWB-103 11/8/2016
Foresight Science & Technology Received Phase I SBIR To Research Novel Method Of Fire Ant Control 11/8/2016
Glenmark Pharma' Experimental GBR 1302-BEAT Demonstrates Potent Anti-Tumor Activity In Preclinical Data Presented At The ESMO Symposium On Immuno-Oncology 11/7/2016
Celyad's CAR-T Candidate Delivers in Early Stage Study 11/7/2016
Gilead (GILD) Drops Another Bombshell, Will Shift R&D Cash Away From Hep C 11/7/2016
Sanofi (SNY) and Novartis AG (NVS) are the Worst Culprits in Reporting Clinical Trial Data, Shire (SHPG) the Best 11/4/2016
La Jolla Pharma (LJPC) Announces Financial Results For The Three And Nine Months Ended September 30, 2016 And Recent Corporate Progress 11/4/2016
Karolinska Development AB Umecrine Cognition Announces Positive Phase 1 Data With GR3027 In Hepatic Encephalopathy 11/3/2016
Towards The Company's First Clinical Trial; Kadimastem Signs Letter Of Intent With Hadassah Medical Center For Performance Of The Clinical Trial In ALS 11/3/2016
Trillium Therapeutics Advances TTI-621 Into Phase 1b Cohort Expansion Enrollment 11/3/2016
The $40 Billion NASH Market and the 3 Biotechs That Stand to Profit From it 11/2/2016
10 Drugs That Could be Johnson & Johnson (JNJ)'s New Blockbusters 11/2/2016
Momenta (MNTA) And Mylan (MYL) Initiate Phase 1 Clinical Trial For M834, A Proposed Biosimilar Of ORENCIA (Abatacept) 11/2/2016
Momenta (MNTA) And Mylan (MYL) Initiate Phase I Clinical Trial For M834, A Proposed Biosimilar Of ORENCIA (Abatacept) 11/2/2016
Paratek Pharma (PRTK) Reports Third Quarter 2016 Financial Results and Provides Clinical Updates 11/2/2016
AveXis (AVXS) Rockets After it Outlines FDA’s Support for a Looming Pivotal Study on SMA 11/2/2016
OncoVent Release: Initiates Clinical Development Program For Anti-MUC1 MAb AR20.5 For Treatment Of Pancreatic Cancer 11/2/2016
Theravance Biopharma (TBPH) Release: New Data For VIBATIV (telavancin) Reported In Presentations At IDWeek 2016 11/1/2016
AmpliPhi Bio (APHB) Granted Small And Medium Enterprise Status By EMA 11/1/2016
Capricor Therapeutics, Inc. Presents Positive 12-Month Results From DYNAMIC At TCT 2016 10/31/2016
Vyome Administers First In-Human Dose Of VB 1953 In U.S. Phase I Clinical Study In Patients With Facial Acne Vulgaris 10/31/2016
ReViral Initiates Phase 1 Clinical Trial Of Potent Oral Inhibitor Against Respiratory Syncytial Virus 10/31/2016
DURECT (DRRX) Announces Update On DUR-928 Development Program 10/31/2016
Adocia Announces Positive Topline Results From A Phase 1b Clinical Trial Measuring The Post-Meal Effect Of Rapid-Acting Human Insulin, Hinsbet U100 10/31/2016
Philogen S.p.A. Receives Orphan Drug Designation For The Treatment Of Soft Tissue Sarcoma 10/28/2016
Upsher-Smith Laboratories Presents Data Characterizing The Pharmacokinetics And Safety/Tolerability Of Investigational Midazolam Nasal Spray (Usl261) In Pediatric Participants With Epilepsy 10/28/2016
Bird Rock Bio Submits Clinical Trial Authorization For The First In Human Clinical Trial For Namacizumab 10/27/2016
Innate Pharma (IPH.PA ): Encouraging Initial Results For IPH4102 Presented At The Third World Congress Of Cutaneous Lymphomas 10/27/2016
ProQR Therapeutics B.V. (PRQR) Announces That QR-010 Meets The Primary Endpoint In A Proof Of Concept Study Of Homozygous F508del Cystic Fibrosis Patients 10/27/2016
Apitope Announces Enrolment Of First Patient In Phase I Trial Of ATX-GD-59 For The Treatment Of Graves' Disease 10/26/2016
F2G Announces Publication Of Initial F901318 Data In Scientific Journal PNAS 10/26/2016
National Center for Child Health And Development Initiates Phase 1/2 Trial Of Green Cross' Idursulfase-Beta ICV For The Treatment Of Hunter Syndrome With Neurocognitive Decline 10/26/2016
Entasis Announces Initiation Of Phase I Clinical Trial Of ETX2514 10/26/2016
Why Aduro Biotech (ADRO)'s Clinical Hold Made Investors So Nervous 10/25/2016
Eurocine Vaccines Announces Initiation Of Clinical Study Of The Nasal Influenza Vaccine Candidate Immunose FLU 10/25/2016
Theravance Biopharma (TBPH) Announces Positive Results Including Biomarker Data From Phase 1 Multiple-Ascending Dose Study Of TD-0714, An Inhibitor Of Neprilysin (NEP) 10/25/2016
SCYNEXIS, Inc. (SCYX) Completes Two Additional Clinical Studies Further Supporting The Favorable Safety Profile Of SCY-078 10/25/2016
AmpliPhi Bio (APHB) Announces Favorable Topline Safety And Tolerability Results From Its Phase I Trial In Patients With Chronic Rhinosinusitis 10/25/2016
FDA Slaps Partial Hold on Bay Area Firm Aduro Biotech (ADRO)'s Cancer Vaccine Trial 10/25/2016
aTyr Pharma Receives FDA Fast Track Designation For Resolaris To Treat Facioscapulohumeral Muscular Dystrophy (FSHD) 10/24/2016
La Jolla Pharma (LJPC) Receives Positive Opinion From European Orphan Committee For LJPC-401 10/24/2016
Newly Published Data Show Biscayne Pharmaceuticals' Novel Antiepileptic Drug Can Eliminate Seizures In Models Of Dravet Syndrome 10/24/2016
Alphamab Starts Clinical Trial On Its First Novel Biologics KN015, A Long-Acting FSH, For In Vitro Fertilization (IVF) 10/24/2016
2 Biotechs Face Key Decisions in Mid-Fourth Quarter 10/21/2016
MorphoSys AG Receives Clinical Milestone For Start Of Phase 1 Trial With Novel Cancer Antibody 10/21/2016
Advaxis (ADXS) Initiates Combination Portion Of Phase I/II Study With Merck & Co. (MRK) 10/20/2016
RadioMedix Successfully Completed The Phase I/ II Clinical Studies For Aminomedix Used For Radiation Kidney Protection During Peptide-Receptor Radionuclide Therapy (PRRT) 10/20/2016
How Pfizer (PFE) is Quietly Rebuilding Its Alzheimer's Pipeline 10/19/2016
Marinus Pharma (MRNS) Release: Ganaxolone Phase I Data Supports Progressing To Phase II In Patients With Status Epilepticus 10/19/2016
Kite Pharma (KITE) Details KTE-C19 Launch Preparedness And Near-Term, Next Generation CAR/TCR Product Candidates At Investor Day 10/19/2016
PharmaEngine, Inc. Announces Initiation Of Phase 1b/2 Trial Of PEP503 (NBTXR3) In Head And Neck Cancer 10/19/2016
After Hep C Flop, Has Vertex (VRTX) Learned From Its Past Mistakes? 10/18/2016
Adaptimmune (ADAP) Announces Initiation Of Triple Tumor Study To Evaluate Its SPEAR T-Cell Therapy Targeting MAGE-A10 10/18/2016
Bayer (BAY) is Pumped Up About Its Potential Cancer Blockbuster But Investors are Skeptical 10/18/2016
A Look at CRISPR, 'Biotech's Biggest Discovery of the Century,' and the 3 Companies Knee Deep in It 10/17/2016
Watch Out, Ionis Pharma (IONS): Could This Little Biotech’s Experimental SMA Treatment Be a Threat? 10/17/2016
Rational Vaccines Release: First Ever Human Trial Of A Live Attenuated Functioning Therapeutic Herpes Vaccine 10/17/2016
First Patient Randomized In Multiple Dose Cohort Of Phase 1/1b Trial With TRANSGENE (ENX:TNG)'s TG1050 In Chronic Hepatitis B Patients 10/17/2016
Celgene (CELG) Release: Oral GED-0301 Phase 1b Results Show Clinical Remission And Endoscopic Response At Week 12 In Patients With Active Crohn's Disease 10/17/2016
After Setback, Adaptimmune (ADAP) Revamps T Cell Study 10/14/2016
Eisai Inc. (ESALF.PK) Release: Preliminary Results From Lenvatinib + Pembrolizumab Phase 1b Clinical Study In Select Solid Tumors Presented At ESMO 2016 10/14/2016
ESMO 2016 Takeaways: Don't Miss Celldex (CLDX), Exelixis (EXEL) and Tesaro (TSRO) 10/13/2016
Chromocell And Astellas (ALPMY) Announce FDA Fast Track Designation And First Subject Dosing With Lead Candidate CC8464/ASP1807 For The Management Of Neuropathic Pain Associated With iSFN 10/13/2016
True North Therapeutics Receives FDA Orphan Drug Designation For TNT009 For The Treatment Of Autoimmune Hemolytic Anemia, Including Cold Agglutinin Disease (CAD) 10/13/2016
C2N Completes Phase I Clinical Study Of C2N-8E12 (ABBV-8E12) Among Individuals With Progressive Supranuclear Palsy 10/13/2016
Adaptimmune (ADAP) Makes Move to Save Ovarian Cancer Study By Readjusting Its Trial Protocol 10/12/2016
TRANSGENE (ENX:TNG) Announces Collaboration With Merck KGaA (MKGAF.PK), Darmstadt, Germany, And Pfizer (PFE) To Evaluate The Combination Of TG4001 With Avelumab In HPV-Positive Head & Neck Cancer In A Phase I/II Study 10/11/2016
Ventrix's Shows Early Signs Of Helping Heart Attack Healing 10/10/2016
Daiichi Sankyo Presents Late-Breaking Phase 1 Data For Novel Investigational HER2-Targeting Antibody Drug Conjugate DS-8201a In T-DM1 Pre-Treated Breast Cancer At The ESMO 2016 Congress 10/10/2016
CytRx (CYTR) Presents Interim Results From On-Going Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial At ESMO 2016 Congress 10/10/2016
Cascadian Therapeutics (ONTY) Announces Presentation Of Tucatinib In Combination Therapy In Patients With Cutaneous HER2+ Metastatic Breast Cancer 10/10/2016
OncoMed (OMED) Presents Interim Phase Ib Data For Ipafricept And Vantictumab In Pancreatic Cancer At The ESMO 2016 Congress 10/10/2016
Endocyte (ECYT) Presents Data On Two Lead Clinical Programs At European Society For Medical Oncology (ESMO) 2016 Congress 10/10/2016
Corvus Pharma Announces Biomarker Findings From Phase I/IIb Study Of Lead Oral Checkpoint Inhibitor CPI-444 Presented At ESMO 2016 Congress 10/10/2016
TRACON Pharma (TCON) Presents Final Updated Phase Ib Results For TRC105 In Combination With Inlyta In Renal Cell Carcinoma At The ESMO 2016 Congress 10/10/2016
Viralytics Ltd (VLA.AX) Updates CAVATAK and KEYTRUDA Combination Clinical Trials At ESMO 2016 10/10/2016
Novartis AG (NVS) Challenges Pfizer (PFE) Full on With New Breast Cancer Data 10/10/2016
ZIOPHARM Oncology (ZIOP) Falls Some More After Experimental Gene Therapy is Tied to 'Higher Than Expected' Toxicity 10/10/2016
4 Small Biotechs That Could Give Gilead (GILD), Merck & Co. (MRK) Pfizer (PFE) Some Competition With NASH 10/7/2016
Global Blood Therapeutics (GBT) Presents GBT440 Data That Continue To Support Durability, Safety And Mechanism Of Action In Sickle Cell Disease 10/7/2016
Kite Pharma (KITE) Presents 12-Month Follow-Up Data From ZUMA-1 Phase I At The European Society For Medical Oncology (ESMO) Annual Congress 10/7/2016
Incyte (INCY) Release: Additional Phase I Data From ECHO-202 Reinforce Durability Of Response In Patients With Treatment-Naive Advanced Or Metastatic Melanoma Treated With Epacadostat In Combination With Keytruda (Pembrolizumab) 10/7/2016
Seattle Genetics (SGEN) And Agensys, Inc., An Affiliate Of Astellas (ALPMY), Highlight Promising Enfortumab Vedotin (ASG-22ME) And ASG-15ME Phase 1 Data In Metastatic Urothelial Cancer At 2016 ESMO Congress 10/7/2016
Exelixis (EXEL) Announces Phase I Trial Results For Cabozantinib In Combination With Nivolumab In Advanced Genitourinary Tumors 10/7/2016
Q Biomed Comments On Its Glaucoma Drug And Industry News In The Ophthalmology Space 10/7/2016



//-->